TransCode Therapeutics has strengthened its scientific leadership by appointing Dr. Phillip D. Zamore to its Scientific Advisory Board. Zamore, a distinguished researcher in RNA interference (RNAi) and co-founder of Alnylam Pharmaceuticals, brings substantial expertise to the oncology-focused company's research efforts.
As Chair of the RNA Therapeutics Institute at UMass Chan Medical School, Zamore is recognized for foundational work in RNA biology and gene silencing mechanisms. His election to the National Academy of Sciences underscores his significant contributions to the field of genetic research.
The appointment signals TransCode's commitment to advancing RNA-targeted cancer therapies. The company's lead therapeutic candidate, TTX-MC138, focuses on treating metastatic tumors that overexpress microRNA-10b, a biomarker associated with metastasis.
Zamore's expertise could potentially accelerate TransCode's development of innovative RNA therapeutic approaches, particularly in addressing challenging genetic targets for cancer treatment. His involvement represents a strategic enhancement of the company's scientific capabilities and research potential.
